Results of autologous and allogeneic SCT in T-PLL patients following CAMPATH-1H
| Patient no. . | Age/sex . | SCT . | Status at SCT . | Conditioning regime . | Current status . | Survival from SCT . |
|---|---|---|---|---|---|---|
| 1 | 49/F | Auto | Second CR | Melphalan/TBI | Died, PCP | 12 mo |
| 2 | 53/M | Auto | Second CR | Melphalan/TBI | Died, relapse | 17 mo |
| 5 | 62/M | Auto | First CR | BEAC | Alive, CR | 7+ mo |
| 6 | 63/F | Auto | First CR | BEAM | Died, CNS relapse | 8 mo |
| 11 | 47/F | Auto | First CR | Melphalan/TBI | Died, relapse | 19 mo |
| 16 | 63/M | Auto | First CR | Cyclo/TBI | Alive, CR | 15+ mo |
| 19 | 58/F | Auto | First CR | BEAM | Alive, CR | 5+ mo |
| 17 | 57/M | Sib Allo | First CR | Cyclo/TBI | Died, TRM | 3 wk |
| 21 | 40/M | Sib Allo | First CR | Cyclo/TBI | Alive, CR | 24+ mo |
| 37 | 50/M | Mini Sib Allo | NR to CAMPATH-1H, PR post mini-BEAM | FDR/melphalan/CAMPATH-1H | Alive, CR DLI | 11+ mo |
| 28 | 51/M | Mini MUD | PR | FDR/melphalan/CAMPATH-1H | Alive, CR | 2+ mo |
| Patient no. . | Age/sex . | SCT . | Status at SCT . | Conditioning regime . | Current status . | Survival from SCT . |
|---|---|---|---|---|---|---|
| 1 | 49/F | Auto | Second CR | Melphalan/TBI | Died, PCP | 12 mo |
| 2 | 53/M | Auto | Second CR | Melphalan/TBI | Died, relapse | 17 mo |
| 5 | 62/M | Auto | First CR | BEAC | Alive, CR | 7+ mo |
| 6 | 63/F | Auto | First CR | BEAM | Died, CNS relapse | 8 mo |
| 11 | 47/F | Auto | First CR | Melphalan/TBI | Died, relapse | 19 mo |
| 16 | 63/M | Auto | First CR | Cyclo/TBI | Alive, CR | 15+ mo |
| 19 | 58/F | Auto | First CR | BEAM | Alive, CR | 5+ mo |
| 17 | 57/M | Sib Allo | First CR | Cyclo/TBI | Died, TRM | 3 wk |
| 21 | 40/M | Sib Allo | First CR | Cyclo/TBI | Alive, CR | 24+ mo |
| 37 | 50/M | Mini Sib Allo | NR to CAMPATH-1H, PR post mini-BEAM | FDR/melphalan/CAMPATH-1H | Alive, CR DLI | 11+ mo |
| 28 | 51/M | Mini MUD | PR | FDR/melphalan/CAMPATH-1H | Alive, CR | 2+ mo |
Auto indicates autologous; PCP, Pneumocystis cariniipneumonia; BEAC: BCNU, etoposide, cytarabine, cyclophosphamide; cyclo, cyclophosphamide; sib, sibling; allo, allogeneic; mini, nonmyeloablative conditioning; DLI, donor lymphocyte infusion. Other abbreviations are defined in the text or in Table 1.